Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TNFerade · 4 trials · 4 indications
| Name | Type | Description |
|---|---|---|
| TNFerade | GENETIC | - |
| TNFerade™ | DRUG | - |
Inclusion Criteria * Age ≥18 years old * Patients with unresectable, locally advanced adenocarcinoma of the pancreas proven by biopsy or cytology (defined as direct extension to the SMA and/or celiac axis with absence of a fat plane between the low-density tumor and these arterial structures, or lo...
Top 20 of 68 competitors
TNFerade is an investigational gene therapy being studied for use in oncology, specifically for rectal cancer, pancreatic cancer, melanoma, and esophageal cancer. It is designed to be combined with treatments such as radiation and chemotherapy. TNFerade is not approved and remains in clinical development.
TNFerade is being developed by Precigen, Inc., a biopharmaceutical company. Precigen's stock is traded under the ticker symbol PGEN. The company is conducting clinical trials to evaluate TNFerade's safety and efficacy in various cancer indications.
TNFerade is in Phase 2 clinical development. It has completed one Phase 2 trial and is also associated with a completed Phase 3 trial for pancreatic cancer. TNFerade is investigational and has not been approved by regulatory authorities.
TNFerade has completed several clinical trials, including NCT00051467 for pancreatic cancer, NCT00051480 for esophageal cancer, NCT00137878 for rectal cancer, and NCT00261404 for melanoma. All trials were conducted in the United States and enrolled adults aged 18 years and older.
TNFerade is a gene therapy designed to deliver the gene for tumor necrosis factor-alpha, a protein that can damage tumor blood vessels and stimulate an immune response against cancer cells. It is administered directly into tumors and is being studied in combination with radiation and chemotherapy.